Skip to main content

Advertisement

Table 2 Comparison of glucose variability in the two groups between baseline and endpoint

From: A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin

Variables Dapagliflozin (n = 14) DPP-4 inhibitors (n = 15) Change difference between groups p value
Baseline Endpoint Mean change (95% CI) Baseline Endpoint Mean change (95% CI)
MAGE (mg dL−1) 86.0 ± 29.4 91.0 ± 34.2 5.0 (−11.6 to 21.7) 89.8 ± 24.1 105.0 ± 30.9 15.2 (−3.8 to 34.3) 0.39
24-h mean blood glucose (mg dL−1) 147.4 ± 26.6 144.6 ± 22.7 −2.8 (−13.6 to 8.0) 150.5 ± 21.8 155.2 ± 26.1 4.7 (−7.1 to 16.4) 0.32
24-h SD values glucose levels 35.3 ± 11.4 39.1 ± 11.7 3.9 (−1.7 to 9.4) 37.5 ± 8.5 43.6 ± 11.7 6.1 (0.0 to 12.3) 0.56
24-h AUC > 180 (mg dL−1 day−1) 6.9 ± 6.3 6.9 ± 6.1 −0.1 (−4.0 to 3.9) 7.3 ± 6.3 11.6 ± 10.0 4.2 (0.6 to 7.8) 0.09
24-h AUC < 70 (mg dL−1 day−1) 0 (0–0) 0.1 (0–0.3) 0 (−0.5 to 1.0) 0 (0–0.1) 0 (0–0.1) 0.0 (−1.0 to 0.5) 0.21
Nighttime AUC < 70 (mg dL−1 day−1) 0 (0–0) 0 (0–0.4) 0 (0 to 1.0) 0 (0–0) 0 (0–0) 0.0 (−0.2 to 1.0) 0.05
The total insulin dose (U kg−1) 0.23 ± 0.19 0.23 ± 0.21 0.00 (−0.03 to 0.02) 0.25 ± 0.13 0.25 ± 0.13 0.00 (−0.01 to 0.01) 0.64
  1. Baseline data are presented as the mean ± SD or median (25–75% CI). p values: mean changes from baseline to the end of the study between the Dapagliflozin group and the DPP-4 inhibitors group.  Mann–Whitney U test
  2. MAGE mean amplitude of glycemic excursions, 24-h all day, SD standard deviation, AUC area under the curve, nighttime 00:00 to 08:00 h